Value of Life Sciences Innovation
Research Program
Value of Life Sciences Innovation
Program Leadership
Spotlight on PBMs View All
Journal Article
Cost Sharing for Preferred Branded Drugs in Medicare Part D
Featured Experts: Erin Trish
In The News View All
Modern Healthcare
Smaller PBMs are facing challenges gaining market share, Joyce says
Featured Experts: Geoffrey Joyce
KFF Heath News
Sood explains why many states capped insulin costs
Featured Experts: Neeraj Sood
BioSpace
Joyce explains how independent pharmacies are being squeezed by PBM practices
Featured Experts: Geoffrey Joyce
Boston Globe
Independent pharmacies struggle as major PBMs steer profitable orders to their own pharmacies, Qato says
Featured Experts: Dima M. Qato
Marketplace
Sood points to conflict of interest in PBMs manufacturing drugs
Featured Experts: Neeraj Sood
Featured Perspective
Medicare Drug Price Negotiations Need Something New: A Floor
Adding a floor price mechanism would protect valuable innovation and effectively give future generations of patients a seat at the negotiating table.
Experts: Darius Lakdawalla
Featured White Papers View All
Impacts of First-in-Class Drug Approvals on Future in-Class Innovation
Experts: Alison Sexton Ward, Karen Van Nuys, Darius Lakdawalla